{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:03:58Z","timestamp":1794002638651,"version":"4.8.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jcyt.2025.01.017","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:08:15Z","timestamp":1739300895000},"page":"678-685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The current state of Cytotherapy and the field of cell and gene therapy"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-6263","authenticated-orcid":false,"given":"William Y.K.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezzah Mohamed","family":"Muzammil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.01.017_bib0001","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease \u2014 A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0002","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0003","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1016\/j.cell.2024.09.004","article-title":"Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41421-024-00662-3","article-title":"Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue","volume":"10","author":"Wu","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0005","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0006","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0007","unstructured":"Schneider J. Realizing New Miracles: Gene Therapy Trends in 2024 and Beyond. https:\/\/AcrpnetOrg\/2023\/12\/19\/Realizing-New-Miracles-Gene-Therapy-Trends-in-2024-and-Beyond 2023."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0008","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","article-title":"Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"391","author":"Eichler","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0009","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0010","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2021.618406","article-title":"Base and Prime Editing Technologies for Blood Disorders","volume":"3","author":"Antoniou","year":"2021","journal-title":"Front Genome Ed"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0012","article-title":"Breaking genetic shackles: The advance of base editing in genetic disorder treatment","volume":"15","author":"Xu","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0013","unstructured":"FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease.Https:\/\/WwwFdaGov\/News-Events\/Press-Announcements\/Fda-Approves-First-Mesenchymal-Stromal-Cell-Therapy-Treat-Steroid-Refractory-Acute-Graft-versus-Host 2024."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0014","unstructured":"Approved Cellular and Gene Therapy Products.Https:\/\/WwwFdaGov\/Vaccines-Blood-Biologics\/Cellular-Gene-Therapy-Products\/Approved-Cellular-and-Gene-Therapy-Products 2024."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0015","unstructured":"AMTAGVI | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/amtagvi (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0016","unstructured":"Study Details | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT05727904 (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0017","unstructured":"AUCATZYL | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/aucatzyl (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0018","unstructured":"BEQVEZ | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/beqvez (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0019","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","article-title":"Fidanacogene Elaparvovec: First Approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0020","unstructured":"CASGEVY | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/casgevy (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0021","unstructured":"FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDA n.d. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0022","unstructured":"Casgevy | European Medicines Agency (EMA) n.d. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/casgevy#authorisation-details (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0023","unstructured":"ELEVIDYS | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/tissue-tissue-products\/elevidys (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0024","unstructured":"KEBILIDI | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/kebilidi (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0025","unstructured":"LENMELDY | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/lenmeldy (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0026","unstructured":"RYONCIL | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/ryoncil (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0027","unstructured":"SYMVESS | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/symvess (accessed January 15, 2025)."},{"issue":"2","key":"10.1016\/j.jcyt.2025.01.017_bib0028","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jamasurg.2024.4893","article-title":"Bioengineered Human Arteries for the Repair of Vascular Injuries","volume":"160","author":"Moore","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0029","unstructured":"TECELRA | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecelra (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0030","unstructured":"Cellular & Gene Therapy Guidances | FDA n.d. https:\/\/www.fda.gov\/vaccines-blood-biologics\/biologics-guidances\/cellular-gene-therapy-guidances (accessed January 15, 2025)."},{"key":"10.1016\/j.jcyt.2025.01.017_bib0031","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41587-024-02357-2","article-title":"Biotech financing: darkest before the dawn","volume":"42","author":"Senior","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.jcyt.2025.01.017_bib0032","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcyt.2020.08.008","article-title":"Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study","volume":"23","author":"Albu","year":"2021","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.017_bib0033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcyt.2020.09.012","article-title":"Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1\/2 pilot study","volume":"23","author":"Yang","year":"2021","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.jcyt.2025.01.017_bib0034","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcyt.2021.01.001","article-title":"Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles","volume":"23","author":"Gimona","year":"2021","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.jcyt.2025.01.017_bib0035","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcyt.2020.11.007","article-title":"Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition","volume":"23","author":"Galipeau","year":"2021","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.017_bib0036","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jcyt.2020.09.007","article-title":"Current evidence on mesenchymal stem cell therapy for traumatic spinal cord injury: systematic review and meta-analysis","volume":"23","author":"Muthu","year":"2021","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.jcyt.2025.01.017_bib0037","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jcyt.2020.12.009","article-title":"Pre-clinical investigation of mesenchymal stromal cell-derived extracellular vesicles: a systematic review","volume":"23","author":"Shekari","year":"2021","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.017_bib0038","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jcyt.2020.09.004","article-title":"Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem\/stromal cells from perinatal and adult tissue sources","volume":"23","author":"Hoang","year":"2021","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.jcyt.2025.01.017_bib0039","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jcyt.2021.03.005","article-title":"The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and efficacy","volume":"23","author":"Law","year":"2021","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.jcyt.2025.01.017_bib0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jcyt.2020.08.012","article-title":"Ex vivo-expanded highly pure ABCB5+ mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data","volume":"23","author":"Kerstan","year":"2021","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.jcyt.2025.01.017_bib0041","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jcyt.2021.12.003","article-title":"Mechanism for the attenuation of neutrophil and complement hyperactivity by MSC exosomes","volume":"24","author":"Loh","year":"2022","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.017_bib0042","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jcyt.2020.07.004","article-title":"Indirect co-culture of lung carcinoma cells with hyperthermia-treated mesenchymal stem cells influences tumor spheroid growth in a collagen-based 3-dimensional microfluidic model","volume":"23","author":"Dhiman","year":"2021","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.jcyt.2025.01.017_bib0043","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jcyt.2021.05.009","article-title":"Human mesenchymal stromal cells small extracellular vesicles attenuate sepsis-induced acute lung injury in a mouse model: the role of oxidative stress and the mitogen-activated protein kinase\/nuclear factor kappa B pathway","volume":"23","author":"Chen","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0044","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jcyt.2024.03.003","article-title":"CAR-T cell expansion platforms yield distinct T cell differentiation states","volume":"26","author":"Song","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0045","series-title":"Proceedings of the International Society for Cell & Gene Therapy (ISCT) Annual Meeting Roundtable held in May 2023, Palais des Congr\u00e8s de Paris, Organized. Cytotherapy, vol. 26","first-page":"413","article-title":"Failure to launch commercially-approved mesenchymal stromal cell therapies: what's the path forward?","author":"Robb","year":"2024"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0046","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcyt.2023.11.001","article-title":"Influence of the isolation method on characteristics and functional activity of mesenchymal stromal cell-derived extracellular vesicles","volume":"26","author":"Malvicini","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0047","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcyt.2023.11.008","article-title":"Assessment and comparison of viability assays for cellular products","volume":"26","author":"Cai","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0048","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jcyt.2024.02.021","article-title":"Good Manufacturing Practice\u2013compliant human induced pluripotent stem cells: from bench to putative clinical products","volume":"26","author":"Novoa","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0049","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcyt.2024.07.006","article-title":"Automation preserves product consistency and quality for the formulation, fill, and finish of T cell-based therapies","volume":"26","author":"Park","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0050","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jcyt.2024.05.007","article-title":"International Society for Cell and Gene Therapy Clinical Translation Committee recommendations on mesenchymal stromal cells in graft-versus-host disease: easy manufacturing is faced with standardizing and commercialization challenges","volume":"26","author":"Alsultan","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0051","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jcyt.2024.04.069","article-title":"Calcium chloride declotted human platelet lysate promotes the expansion of mesenchymal stromal cells and allows manufacturing of immunomodulatory active extracellular vesicle products","volume":"26","author":"Mouloud","year":"2024","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.jcyt.2025.01.017_bib0052","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jcyt.2020.12.002","article-title":"Generating natural killer cells for adoptive transfer: expanding horizons","volume":"23","author":"Kundu","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2022.12.003","article-title":"The NK-92 cell line\u201430 years later: its impact on natural killer cell research and treatment of cancer","volume":"25","author":"Klingemann","year":"2023","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.017_bib0054","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcyt.2020.11.008","article-title":"Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States","volume":"23","author":"Iglesias-Lopez","year":"2021","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.017_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcyt.2020.10.001","article-title":"Advances in generation of three-dimensional skin equivalents: pre-clinical studies to clinical therapies","volume":"23","author":"Choudhury","year":"2021","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.jcyt.2025.01.017_bib0056","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.jcyt.2025.01.017_bib0057","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jcyt.2022.03.007","article-title":"Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products","volume":"24","author":"Cuende","year":"2022","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.jcyt.2025.01.017_bib0058","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jcyt.2021.04.003","article-title":"Advances in automated cell washing and concentration","volume":"23","author":"Li","year":"2021","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.017_bib0059","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcyt.2020.10.006","article-title":"Non-invasive monitoring of the kinetic infiltration and therapeutic efficacy of nanoparticle-labeled chimeric antigen receptor T cells in glioblastoma via 7.0-Tesla magnetic resonance imaging","volume":"23","author":"Xie","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcyt.2023.08.013","article-title":"Astragaloside IV promotes exosome secretion of endothelial progenitor cells to regulate PI3KR2\/SPRED1 signaling and inhibit pyroptosis of diabetic endothelial cells","volume":"26","author":"Xiong","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcyt.2023.09.002","article-title":"Stem cell-derived exosomes for traumatic spinal cord injury: a systematic review and network meta-analysis based on a rat model","volume":"26","author":"Shang","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0062","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jcyt.2023.10.002","article-title":"Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and\/or lymphopenia (RELEASE NCT04578210)","volume":"26","author":"Ferreras","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0063","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcyt.2023.11.013","article-title":"Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy","volume":"26","author":"Kapadia","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0064","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jcyt.2024.05.022","article-title":"Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee","volume":"26","author":"Madrid","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0065","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jcyt.2024.03.480","article-title":"Safety and potential efficacy of expanded mesenchymal stromal cells of bone marrow and umbilical cord origins in patients with chronic spinal cord injuries: a phase I\/II study","volume":"26","author":"Awidi","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0066","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jcyt.2024.04.067","article-title":"The science and practice of current environmental risk assessment for gene therapy: a review","volume":"26","author":"Liu","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0067","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jcyt.2024.02.027","article-title":"Effects of mitochondrial transplantation on chronic pressure wound healing in a human patient","volume":"26","author":"Taner","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0068","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jcyt.2023.12.007","article-title":"Extracellular vesicles from adipose mesenchymal stem cells target inflamed lymph nodes in experimental autoimmune encephalomyelitis","volume":"26","author":"Turano","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0069","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcyt.2023.11.007","article-title":"Human CD4+CD25+ T cells expressing a chimeric antigen receptor against aberrant superoxide dismutase 1 trigger antigen-specific immunomodulation","volume":"26","author":"Graber","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jcyt.2023.09.003","article-title":"Extracellular vesicles from induced pluripotent stem cell-derived mesenchymal stem cells enhance the recovery of acute kidney injury","volume":"26","author":"Hong","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.01.017_bib0071","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jcyt.2024.03.489","article-title":"Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical sibling donors for hematological malignancies in 6064 adults from 2003 to 2020: different impacts on survival according to time period","volume":"26","author":"Konuma","year":"2024","journal-title":"Cytotherapy"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925000581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925000581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:02:12Z","timestamp":1750165332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925000581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1465324925000581"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.01.017","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current state of Cytotherapy and the field of cell and gene therapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}